Edition:
United Kingdom

LifeVantage Corp (LFVN.OQ)

LFVN.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
16 Feb 2018
Change (% chg)

$-0.10 (-2.35%)
Prev Close
$4.25
Open
$4.19
Day's High
$4.27
Day's Low
$4.14
Volume
3,858
Avg. Vol
10,705
52-wk High
$6.94
52-wk Low
$2.86

Chart for

About

LifeVantage Corporation is a science-based network marketing company. The Company focuses on helping people achieve their health, wellness and financial independence goals. The Company provides products and a financially rewarding direct sales business opportunity to customers and independent distributors seeking a healthy... (more)
No analyst recommendations are available for .

Overall

Beta: 0.55
Market Cap(Mil.): $66.87
Shares Outstanding(Mil.): 14.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 22.59 16.64
EPS (TTM): -- -- --
ROI: -- 12.23 10.66
ROE: -- 15.61 14.30

BRIEF-LifeVantage Announces Q2 Earnings Per Share $0.02

* LIFEVANTAGE ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

07 Feb 2018

BRIEF-Lifevantage Says Products Available For First Time Ever Throughout China

* LIFEVANTAGE CORP - LIFEVANTAGE PRODUCTS AVAILABLE FOR FIRST TIME EVER THROUGHOUT CHINA

01 Feb 2018

BRIEF-Lifevantage Says ‍Providing Notice Of Plaintiffs' Proposed Voluntary Dismissal Of Shareholder Derivative Actions

* LIFEVANTAGE SAYS ‍PROVIDING NOTICE OF PLAINTIFFS' PROPOSED VOLUNTARY DISMISSAL OF SHAREHOLDER DERIVATIVE ACTIONS Source text: (http://bit.ly/2D7WFIx) Further company coverage:

08 Jan 2018

BRIEF-Lifevantage reports $5 mln share repurchase program

* LIFEVANTAGE CORP - ‍EXPECTS TO FUND REPURCHASE PROGRAM THROUGH CASH ON HAND AND FUTURE CASH FLOW FROM OPERATIONS​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-LifeVantage announces financial results for the first quarter

* LifeVantage announces financial results for the first quarter of fiscal 2018

08 Nov 2017

BRIEF-Lifevantage appoints Kevin Mcmurray as general counsel

* Lifevantage appoints Kevin Mcmurray as general counsel Source text for Eikon: Further company coverage:

02 Oct 2017

BRIEF-Lifevantage Q4 earnings per share $0.01

* Lifevantage announces financial results for the fourth fiscal quarter and full fiscal year 2017

07 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.15 +1.92
AstraZeneca plc (AZN.L) 4,756.50 +17.00
Prestige Brands Holdings, Inc. (PBH.N) $35.21 +0.39
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF80.26 -0.54
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Roche Holding Ltd. (ROG.S) CHF224.50 -1.00
Roche Holding Ltd. (RO.S) CHF228.80 -1.40
Abbott Laboratories (ABT.N) $60.17 +0.67

Earnings vs. Estimates